2016
DOI: 10.1021/acs.jmedchem.6b00177
|View full text |Cite
|
Sign up to set email alerts
|

Discovery and Structure–Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists

Abstract: Herein, we report studies leading to the discovery of the neoseptins and a comprehensive examination of the structure–activity relationships of this new class of small molecule mouse Toll-like receptor 4 (mTLR4) agonists. The compound class, which emerged from screening a α-helix mimetic library, stimulate the immune response, act by a well-defined mechanism (mouse TLR4 agonist), are easy to produce and structurally manipulate, exhibit exquisite structure–activity relationships, are non-toxic, and elicit impro… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
27
0
1

Year Published

2017
2017
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 33 publications
(29 citation statements)
references
References 65 publications
0
27
0
1
Order By: Relevance
“…Because our results are unable to completely explain the usefulness of S100A8 and S100A9, it is imperative to unveil the drug-resistance mechanism for personal therapy and develop novel resistant drugs (including peptides and chemical compounds) based on TLR4 agonists, such as S100A8 and S100A9. Therapeutic drugs that target TLR4 and S100A8 or S100A9 have been examined, and potential candidate agents have been discovered ( 37 40 ). New materials based on our research can proceed in the quest for activators that induce TLR4-mediated apoptotic signal transduction and inhibitors of transcription-associated components that control transcription of the FIP1L1-PDGFRα+ gene.…”
Section: Discussionmentioning
confidence: 99%
“…Because our results are unable to completely explain the usefulness of S100A8 and S100A9, it is imperative to unveil the drug-resistance mechanism for personal therapy and develop novel resistant drugs (including peptides and chemical compounds) based on TLR4 agonists, such as S100A8 and S100A9. Therapeutic drugs that target TLR4 and S100A8 or S100A9 have been examined, and potential candidate agents have been discovered ( 37 40 ). New materials based on our research can proceed in the quest for activators that induce TLR4-mediated apoptotic signal transduction and inhibitors of transcription-associated components that control transcription of the FIP1L1-PDGFRα+ gene.…”
Section: Discussionmentioning
confidence: 99%
“…Motivated by the ring structure of the highly unstable triacetone triperoxide, we envisaged the synthesis also of nine‐membered peroxides, so‐called 1,2,4‐trioxononanes. The C 4 ‐linked phenol 10 was converted with caroate into the hydroperoxide 11 in 79 % yield. The ferric chloride catalyzed peroxyacetalization with three ketones delivered the 1,2,4‐trioxocanes 12 a – 12 c in low yields (Scheme ).…”
Section: Methodsmentioning
confidence: 99%
“…Synthetic compounds with a linear scaffold instead of glucosamine disaccharide such as ER-112022 [ 57 ] are active as TLR4 agonist, thus showing that the disaccharide connecting the two anionic phosphates can be substituted by chemical spacers of different chemical structure and with increased conformational mobility. More recently, new classes of non-LPS-like small molecules, the neoseptins [ 58 , 59 ], Euodenine A and analogues [ 60 ], have been reported to be MD-2-dependent TLR4 agonists [ 5 , 59 , 61 , 62 , 63 ].…”
Section: Structure-activity Relationship In Natural and Synthetic mentioning
confidence: 99%